SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 1417.
  • 2
    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled study. Ann Intern Med 1999; 130: 47886.
  • 3
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A study of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 2539.
  • 4
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 158693.
  • 5
    Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000; 356: 38590.
  • 6
    Mease P, Kivitz A, Burch F, Siegel E, Cohen S, Burge D. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (ENBREL): results of a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S90.
  • 7
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 6: 72735.
  • 8
    Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000; 34: 1614.
  • 9
    Lebsack ME, Hanna RK, Lange MA, Newman A, Ji W, Korth-Bradley JM. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers [abstract]. Pharmacotherapy 1997; 17: 11189.
  • 10
    Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis [abstract]. Clin Pharmacol Ther 2002a; 71: P84.
  • 11
    Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Fifty mg once weekly subcutaneous regimen of etanercept will yield an overlapping steady state time-concentration profile with 25 mg twice weekly dosing [abstract]. Clin Pharmacol Ther 2002b; 71: P90.
  • 12
    Nestorov I, Lee H, Kimko HC, Rogge M, Wang D, Peck CC. Clinical trial simulation of a 50 mg once weekly subcutaneous dosing regimen with etanercept (Enbrel) [abstract]. Ann Rheum Dis 2002; 61 Suppl 1: 71.
  • 13
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 14
    Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.